University of North Carolina Lineberger Comprehensive Cancer Center researchers will be well-represented at the 61st American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 7-10.
ASH is the world’s largest professional society of hematologists and is dedicated to understanding, diagnosing, treating and preventing blood disorders. The society expects more than 20,000 hematologists and health care professionals from all 50 states and more than 100 countries to attend the meeting.
UNC Lineberger members who’ll be presenting findings at the meeting include:
Barbara Savoldo, MD, PhD, assistant director of the UNC Lineberger Clinical Immunotherapy Program and professor of pediatrics in the UNC School of Medicine Division of Hematology/Oncology, will be one of three speakers in a scientific session called “Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy.” The program will be offered twice on Dec. 7, 7:30-9 a.m. and 4-5:30 p.m. As part of the session she will present findings from a clinical study of a CAR-T cell immunotherapy for Hodgkin lymphoma: “Novel Immunotherapeutic Approaches for Hodgkin Lymphoma.”
Matthew Foster, MD, associate professor in the UNC School of Medicine Division of Hematology/Oncology, will deliver results on Dec. 7, 5:30-7:30 p.m., from a study into a potential blood test to predict relapse of acute myeloid leukemia: “Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML).”
Sonia J. Laurie, PhD, BSc, postdoctoral research associate at UNC Lineberger, will present data Dec. 7, 5:30-7:30 p.m., from the abstract: “Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract.”
Timothy J. Voorhees, MD, clinical fellow in the UNC School of Medicine Division of Hematology/Oncology, will share data on Dec. 8, 6-8 p.m., from a clinical study of an immunotherapy, a checkpoint inhibitor, for patients with heavily pre-treated relapsed and refractory Hodgkin lymphoma after receiving CD30 CAR-T cell immunotherapy: “Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.”
Danny Bruce, PhD, research associate at UNC Lineberger, is presenting findings in a session from Dec. 8, 6-8 p.m. from a study “Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD.”
Joshua Zeidner, MD, assistant professor in the UNC School of Medicine Division of Hematology/Oncology, will present data on Dec. 9, 5 p.m., from a phase II trial studying the outcome of using a checkpoint inhibitor therapy after chemotherapy for patients with relapsed or refractory acute myeloid leukemia: “Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML.”
The annual meeting’s program is available online: https://www.hematology.org/Annual-Meeting/Abstracts/.